Unleashing the Potential of Tau Oligomer Inhibition™
Oligomerix® Vision
To discover novel and differentiated small molecules and biomarkers focused on tau oligomer inhibition for the disease-modifying treatment of Alzheimer’s disease and other related neurodegenerative diseases
News & Upcoming Events
September 15, 2020: Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer’s Disease Therapy
May 8, 2020: Oligomerix Announces Appointment of Robert Foerster, Former Pfizer Executive, as Chief Financial Officer
Our recent publication of an in vivo proof-of-concept study showed that an oral small molecule drug for Alzheimer’s disease reduced the level of tau aggregates linked to neurotoxicity and disease progression.
Click here to read the full publication